Disposition of 18750 shares by Chung Jane of Sutro Biopharma subject to Rule 16b-3
| STRO Stock | USD 2.65 0.04 1.49% |
About 60% of Sutro Biopharma's investor base is looking to short. The analysis of the overall investor sentiment regarding Sutro Biopharma suggests that many traders are alarmed. Sutro Biopharma's investing sentiment overview a quick insight into current market opportunities from investing in Sutro Biopharma. Many technical investors use Sutro Biopharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Sutro |
Filed transaction by Sutro Biopharma Officer: President And Coo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cash Flow Correlation
Sutro Biopharma's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Sutro Biopharma's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Sutro Biopharma Fundamental Analysis
We analyze Sutro Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sutro Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sutro Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Sutro Biopharma is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Sutro Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Sutro Biopharma stock to make a market-neutral strategy. Peer analysis of Sutro Biopharma could also be used in its relative valuation, which is a method of valuing Sutro Biopharma by comparing valuation metrics with similar companies.
Peers
Sutro Biopharma Related Equities
| TFFP | Tff Pharmaceuticals | 9.68 | ||||
| ELYM | Eliem Therapeutics | 1.30 | ||||
| INBX | Inhibrx | 2.37 | ||||
| ELVN | Enliven Therapeutics | 4.05 |
Check out Sutro Biopharma Hype Analysis, Sutro Biopharma Correlation and Sutro Biopharma Performance. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Revenue Per Share 2.253 | Quarterly Revenue Growth (0.50) | Return On Assets (0.18) | Return On Equity (1.11) |
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.